Coty's Sales Weakness Persists, Guidance Dims Visibility

What happened

Coty's FY2025 results already showed a 4% revenue decline and a swing to a net loss driven by impairments and weak Consumer Beauty performance, with the stock down over 50% in the past year. The company's subsequent fiscal Q4 report did not alter this concerning sales trend, as revenues continued to slide, pressuring earnings. Management's guidance for Q1 suggests further weakness ahead, and the absence of a full-year FY2027 outlook adds to investor unease. The brand portfolio remains volatile, with subdued consumer interest in key licensed names like Calvin Klein, Gucci, and Burberry, undermining a core growth pillar. This pattern confirms that the execution challenges and category headwinds identified in the earlier DeepValue report have yet to reverse.

Implication

The persistent sales decline and weak forward guidance indicate that management's turnaround efforts are not yet gaining traction, increasing the risk of further earnings deterioration. The lack of FY2027 guidance reduces visibility and could lead to continued negative estimate revisions, keeping the stock under pressure. However, the deeply depressed valuation—trading below book value and a no-growth DCF estimate—and ongoing strategic review of Consumer Beauty may provide some downside protection if asset sales or cost cuts materialize. Still, with high leverage and fragile cash flows, the margin of safety is thin, and any misstep could trigger further credit deterioration. A more constructive stance would require concrete evidence of prestige fragrance re-acceleration, successful rationalization of Consumer Beauty, and a clear path to deleveraging, none of which are currently evident.

Thesis delta

The WAIT stance from the prior report is reinforced by the new information, which shows that revenue declines have continued into the most recent quarter and guidance points to more near-term weakness. The absence of a full-year FY2027 outlook introduces additional uncertainty and suggests management lacks confidence in a quick recovery. This tilts the risk-reward further negative, though the depressed valuation and potential for strategic actions keep the stock from a clear SELL designation at this time.